NeoGenomics Adopts Ultima Genomics Platform to Expand Sequencing-Based Oncology Diagnostics
NeoGenomics has partnered with Ultima Genomics to integrate the UG 100 sequencing platform into its Cambridge, UK innovation center, aiming to develop a new range of clinical oncology tests. The collaboration will leverage ppmSeq technology for applications requiring high sequencing fidelity at low DNA input, including liquid biopsy and minimal residual disease (MRD) testing.
Ultima’s UG 100 platform, recently updated with the Solaris chemistry, reportedly delivers over 10 billion reads per wafer with a cost of $0.24 per million reads, and supports 30X coverage from as little as 2 nanograms of DNA. NeoGenomics will use the platform to support R&D across the cancer care continuum, citing the system’s fit for high-throughput, high-accuracy demands.
See also: 100 Billion Reads Per Day: Ultima Genomics Expands Sequencing Capacity
According to Ultima, the collaboration supports its push into clinical genomics markets where cost-efficient, ultra-deep sequencing enables earlier detection and more comprehensive variant analysis. The UG 100 is currently deployed at over 15 sites and has been used in large-scale projects involving Broad Institute, Regeneron Genetics Center, and Tahoe Therapeutics (formerly Vevo).
